Lanean...
Evidence to date: talazoparib in the treatment of breast cancer
Approximately 5–10% of all patients diagnosed with breast cancer have germline BRCA1/2 mutations, which make their disease more susceptible to DNA-damaging agents and a new class of drugs known as poly(ADP-ribose) polymerase (PARP) inhibitors. Talazoparib is a new PARP inhibitor that has been recent...
Gorde:
| Argitaratua izan da: | Onco Targets Ther |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6612288/ https://ncbi.nlm.nih.gov/pubmed/31303769 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S184971 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|